Genomic Profile and Clinical Outcomes in Acute Myeloid Leukemia with Monosomal Karyotype
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125845 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Collins Wangulu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Princess Margaret Cancer Biobank (PMCB), University Health Network, Toronto, ON M5G 2C4, Canada. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Monosomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The biology of Monosomal Karyotype Acute Myeloid Leukemia (MK AML) remains unclear, and its mutational profile has not been exclusively assessed. We sought to determine the genomic profile of MK AML patients and its correlation with overall survival (OS). We conducted a retrospective study involving 664 AML patients, identifying 156 (23.5%) with MK AML. The most common monosomies were -17 (41%) and -7 (37%), with 149 (95%) and 138 (88%) having myelodysplasia-related (MR) cytogenetics and complex karyotype (CK), respectively. Frequent mutations included TP53 (69%), DNMT3A (19%), TET2 (13%), and IDH1 (7%). Patients with MK AML with TP53 mutation (TP53 Mut) had shorter OS compared to those with TP53 wild-type (WT) (median OS, 3.9 versus 9.2 months, p = 0.002). Our validation study further supports this finding. There was no significant difference in OS related to the presence or absence of CK (p = 0.252), MR mutations (p = 0.252), DNMT3A (p = 0.264), TET2 (p = 0.264), and IDH1 (p = 0.183) alterations. Co-mutation with novel EPI6 and TAZI signature alterations did not significantly impact OS among MK AML TP53 Mut patients, suggesting that TP53 Mut remains the dominant driver of outcome in this subgroup. In conclusion, MK AML is a genotypically diverse and high-risk group, with MK AML TP53 Mut indicating worse prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Princess Margaret Cancer Biobank (PMCB), University Health Network, Toronto, ON M5G 2C4, Canada.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1V4, Canada.
- Department of Laboratory Hematology, University Health Network, Toronto, ON M5G 2C4, Canada.
- Laboratory Medicine Program, Clinical Laboratory Genetics, University Health Network, Toronto, ON M5G 2C4, Canada.
- Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2C4, Canada.
ORCID-Profile: Ehsan Bahrami Hezaveh, Qianghua Zhou, Hassan Sibai
Zitieren
APA
Wangulu, C., Bahrami Hezaveh, E., Zarif, M., Zhou, Q., Lo, W., Wei, C., Sibai, H., & Chang, H. (2025). Genomic Profile and Clinical Outcomes in Acute Myeloid Leukemia with Monosomal Karyotype. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125845
Vancouver
Wangulu C, Bahrami Hezaveh E, Zarif M, Zhou Q, Lo W, Wei C, et al. Genomic Profile and Clinical Outcomes in Acute Myeloid Leukemia with Monosomal Karyotype. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125845
BibTeX
@article{Wangulu2025,
author = {Wangulu, Collins and Bahrami Hezaveh, Ehsan and Zarif, Mojgan and Zhou, Qianghua and Lo, Winnie and Wei, Cuihong and Sibai, Hassan and Chang, Hong},
title = {Genomic Profile and Clinical Outcomes in Acute Myeloid Leukemia with Monosomal Karyotype},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125845}
}
EUVIMED